Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Breast Cancer, Chest Wall Tumor
Phase PHASE2
Enrollment 46
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

This is a Phase II single center, open-label, non-randomized study in patients with locally recurrent, inoperable, and/or metastatic inflammatory breast cancer with lymphangitic spread to the chest wall. Patients will be treated with pembrolizumab administered as an intravenous infusion at 200 mg in 21-day treatment cycles and oral cyclophosphamide (CTX) 50 mg per day in metronomic administration as a 21 days cycle Forty-six patients will be required for the study. Key inclusion criteria are PDL1 (≥1%) positive and/or tumor infiltrating lymphocyte positive (≥1%) locally advanced "chest wall" breast cancer (with or without distant metastases), who have been treated with chemotherapy or radiation therapy may be eligible for this study. Patients with cutaneous metastases only (with or without evidence of primary tumor) are eligible for the study. Key exclusion criteria included prior anti PD1 or anti CTLA-4 or other immune pathway-targeted therapy. Patients with autoimmune diseases and/or receiving drugs who interfere with the immune system will not be eligible.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Pembrolizumab — Patients will be treated with pembrolizumab administered as an intravenous infusion at 200 mg in 21-day treatment cycles and oral cyclophosphamide (CTX) 50 mg per day in metronomic administration as a 21 days cycle

Primary Outcomes

  • Objective response (Participants will be followed for the duration of treatment, an expected average of 6-months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2020-05-20
Completion: 2025-03-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 46 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: European Institute of Oncology
Contact Information
Study Contact:
Giuseppe Curigliano, MD PhD
+390257489001
giuseppe.curigliano@ieo.it
Bruno Duso, MD
+390257489001
bruno.duso@ieo.it
Giuseppe Curigliano, MD
00390257489001
giuseppe.curigliano@ieo.it
Istituto Europeo di Oncologia
Interventions
  • Drug: Pembrolizumab — Patients will be treated with pembrolizumab administered as an intravenous infusion at 200 mg in 21-day treatment cycles and oral cyclophosphamide (CTX) 50 mg per day in metronomic administration as a 21 days cycle
Study Locations (1 sites)
Istituto Europeo di Oncologia, Milan, 20141 Italy
Eligibility Criteria
Inclusion Criteria: * Histologically proven, PDL1 (≥1%) positive and/or tumor infiltrating lymphocytes (TILs) positive (≥1%), locally advanced "chest wall" breast cancer (with or without distant metastases), who have been treated with chemotherapy or radiation therapy may be eligible for this study. Patients with cutaneous metastases only (with or without evidence of primary tumor) are also eligible; * Patients must have tissue accessible for serial biopsies; * Expected survival of \> 3 months; * Be willing and able to provide written informed consent/assent for the trial. The subject may also provide consent/assent for Future Biomedical Research. However, the subject may participate in the main trial without participating in Future Biomedical Research. Newly-obtained is defined as a specimen obtained up to 6 weeks (42 days) prior to initiation of treatment on Day 1. Subjects for whom newly-obtained samples cannot be provided (e.g. inaccessible or subject safety concern) may submit an archived specimen only upon agreement from the Sponsor; * Be 18 years of age on day of signing informed consent; * Be a female or male subject with IBC with lymphangitic spread to the chest wall. ER, PgR and HER2 status determination is required for enrollment; * Have provided tissue for PD-L1 biomarker analysis from a newly obtained core or excisional biopsy of a tumor lesion (mandatory) and received permission for enrollment from the Core Lab based on the adequacy of the biopsy specimen. Repeat samples may be required if adequate tissue is not provided; * Have measurable metastatic disease based on irRECIST criteria as determined by central radiology review. Tumor lesions situated in a previously irradiated area are considered measurable, if progression has been demonstrated in such lesions. Note: The exact same image acquisition and processing parameters should be used throughout the study; * Have a performance status of 0 or 1 on the ECOG Performance Scale. Assessment should be performed within 10 days of treatment initiation; * Female subjects of childbearing potential (Section 2.9.2) must be willing to use an adequate method of contraception as outlined in Section 2.9.2 - Contraception, for the course of the study through 120 days after the last dose of study medication; * Male subjects childbearing potential (Section 2.9.2) must agree to use an adequate method of contraception as outlined in Section 2.9.2- Contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject; * Female subjects of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; * Patients with hormone receptor-positive and/or HER2-positive breast cancer would be eligible for the study only if their disease is considered refractory to hormonal or anti-HER2 agents, respectively, and no further hormonal or anti-HER2 treatment is indicated; * Demonstrate adequate organ function as defined in protocol, all screening labs should be performed within 10 days of treatment initiation; * Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; * Female subjects of childbearing potential (Section 5.7.2) must be willing to use an adequate method of contraception as outlined in Section 5.7.2 - Contraception, for the course of the study through 120 days after the last dose of study medication. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject; * Male subjects of childbearing potential (Section 5.7.1) must agree to use an adequate method of contraception as outlined in Section 5.7.1- Contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject. Exclusion Criteria: * Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment; * Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment; * Has a known history of active TB (Bacillus Tuberculosis); * Hypersensitivity to pembrolizumab or any of its excipients; * Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier; * Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent. Note 1: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and may qualify for the study. Note 2: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy. * Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer; * Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability; * Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment; * Has known history of, or any evidence of active, non-infectious pneumonitis; * Has an active infection requiring systemic therapy; * Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator; * Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial; * Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment; * Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent; * Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies); * Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \[qualitative\] is detected); * Has received a live vaccine within 30 days of planned start of study therapy. Not
Conditions Breast Cancer, Prostate Cancer, Colorect...
Phase NA
Enrollment 306
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to see if survivors of breast, prostate, colorectal or lymphoma cancer who receive a personal referral to a targeted nutrition and exercise program will be able to eat a healthier diet and be more physically activity.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Other: Fitbit — Participants will be provided with a Fitbit. Self-reported physical activity, location, vital sign and sleep stage information will be collected and monitored every day for up to eight (8) weeks. Data will be synced to the My Wellness Research Software Platform, resulting in a weekly text or phone call check-in, based on participants preference.
  • Behavioral: Nutrition Course: Group Sessions — The nutrition course will follow a combined asynchronous and synchronous approach. The asynchronous component will consist of a pre-recorded session covering educational nutrition content, which will be made available to participants for self-paced learning. This will be followed by a synchronous, 30-60 minute live group education class on nutrition information for cancer survivors, held once per week.
  • Behavioral: Physical Activity Program: Group Sessions — The Physical Activity Program will be held virtually or in-person. This will be a 1-hour biweekly group education class on aerobic and resistance exercise recommendations for cancer survivors.
  • Behavioral: Nutrition Course: One on One Sessions with Registered Dietitian — Participants will be referred to weekly one on one nutrition counseling sessions with a Registered Dietitian. The one on one sessions are anticipated to last 30-60 minutes, based on the needs of the individual.
  • Behavioral: Physical Activity Program: One on One Sessions with an Exercise Physiologist — Participants will be referred to weekly one on one exercise training sessions with an Exercise Physiologist. The one on one sessions are anticipated to last 30-60 minutes, based on the needs of the individual
  • Behavioral: Nutrition and Physical Activity Prescription — Participants will receive a lifestyle medicine prescription pad, developed by the investigators, which serves as a checklist to assist participants in effectively monitoring their dietary habits and physical activity routines. Participants will also receive an 8-week text messages program which will direct participants to a webpage with nutrition and physical activity content.

Primary Outcomes

  • Percentage of Survivors Who Agree to Participate (Up to 8 Weeks)
  • Percentage of Interventions Sessions Completed (Up to 8 Weeks)
  • Percentage of Participants Satisfied with the Intervention (Up to 8 Weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-09-18
Completion: 2027-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 306 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Miami
Collaborators: The Applebaum Foundation
Principal Investigators:
  • Tracy Crane, PhD, RDN (PRINCIPAL_INVESTIGATOR) - University of Miami
Contact Information
Study Contact:
Grey Freylersythe, BS
305-243-9832
g.freylersythe@med.miami.edu
Tracy Crane, PhD, RDN
305-243-8255
tecrane@med.miami.edu
Grey Freylersythe, BS
(305) 243-9832
g.freylersythe@med.miami.edu
University of Miami
Interventions
  • Other: Fitbit — Participants will be provided with a Fitbit. Self-reported physical activity, location, vital sign and sleep stage information will be collected and monitored every day for up to eight (8) weeks. Data will be synced to the My Wellness Research Software Platform, resulting in a weekly text or phone call check-in, based on participants preference.
  • Behavioral: Nutrition Course: Group Sessions — The nutrition course will follow a combined asynchronous and synchronous approach. The asynchronous component will consist of a pre-recorded session covering educational nutrition content, which will be made available to participants for self-paced learning. This will be followed by a synchronous, 30-60 minute live group education class on nutrition information for cancer survivors, held once per week.
  • Behavioral: Physical Activity Program: Group Sessions — The Physical Activity Program will be held virtually or in-person. This will be a 1-hour biweekly group education class on aerobic and resistance exercise recommendations for cancer survivors.
  • Behavioral: Nutrition Course: One on One Sessions with Registered Dietitian — Participants will be referred to weekly one on one nutrition counseling sessions with a Registered Dietitian. The one on one sessions are anticipated to last 30-60 minutes, based on the needs of the individual.
  • Behavioral: Physical Activity Program: One on One Sessions with an Exercise Physiologist — Participants will be referred to weekly one on one exercise training sessions with an Exercise Physiologist. The one on one sessions are anticipated to last 30-60 minutes, based on the needs of the individual
Study Locations (1 sites)
University of Miami, Miami, Florida 33136 United States
Eligibility Criteria
Inclusion Criteria: Inclusion Criteria - Healthcare Providers 1. Provide full- or part-time care in an oncology clinical care setting at Sylvester Comprehensive Cancer Center 2. Utilize the electronic medical record for patient documentation on a regular basis 3. Willing to complete a 30-60-minute interview Inclusion Criteria - Patients 1. 18 years of age or older 2. Any sex/gender 3. Able to provide consent 4. Able to read/understand English or Spanish 5. Diagnosis of breast, prostate, colorectal or lymphoma cancer, 6 months post completion of primary treatment, with no evidence of primary disease 6. Approval from treating oncologist, confirmed via email or in writing 7. Fail to meet at least one of the American Cancer Society guidelines: engaging in \>150 minutes of moderate-to-vigorous physical activity per week for the prior month or consuming at least 3 cups of vegetables and 2 cups of fruit per day over the past month. 8. Internet access on a smart phone, tablet, or computer 9. Agree to be randomly assigned to any study group Exclusion Criteria: 1. Less than 18 years of age 2. Unable to provide consent 3. Unable to read/understand English or Spanish 4. Any contraindication for diet change or exercising as determined by physician 5. Blank 6. Engaging in \>150 minutes of moderate to vigorous physical activity on average per week for the prior month 7. Meeting the American Cancer Society diet recommendations (3 cups of vegetables or legumes, 2 cups of fruit, 2 serving whole grain per day, and limited red/processed meats, sugar-sweetened beverages, and highly processed foods) for the prior month 8. History of dementia or major psychiatric disease which would interfere with study participation 9. History of recent (≤1 yr) stroke, myocardial infarction or congestive heart failure 10. Eastern Cooperative Oncology Group (ECOG) score of \>2 11. Severe lymphedema as determined by physician 12. Receiving physical therapy treatment
Conditions Breast Cancer
Phase NA
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to evaluate the effectiveness of an intervention to promote breast cancer screening mammography among women in one community on the Navajo Nation. The intervention is Tablet-based Education to improve the Acceptance of Mammography (TEAM). TEAM encompasses culturally-tailored mammography education modules that were developed using a community-based participatory research process. Women will be randomized to receive TEAM or TEAM + Navigation. Navigation involves monthly 1:1 support from a Diné peer-navigator.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Navigation — Navigation is provision of 1:1 support from a Diné peer-navigator
  • Behavioral: TEAM — TEAM encompasses culturally tailored mammography education modules

Primary Outcomes

  • Number of participants with mammography (3 months post baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-02
Completion: 2028-03
Eligibility
Age: 40 Years – 74 Years
Sex: FEMALE
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Johns Hopkins Bloomberg School of Public Health
Collaborators: Genentech Foundation
Principal Investigators:
  • Katie Nelson, PhD (PRINCIPAL_INVESTIGATOR) - Johns Hopkins University
Contact Information
Study Contact:
Katie Nelson, PhD
410-955-6931
knelso46@jhmi.edu
Kristen Mitchell, MS
928-674-5051
Navajo Nation Center for Indigenous Health
Interventions
  • Behavioral: Navigation — Navigation is provision of 1:1 support from a Diné peer-navigator
  • Behavioral: TEAM — TEAM encompasses culturally tailored mammography education modules
Study Locations (1 sites)
Navajo Nation Center for Indigenous Health, Chinle, Arizona 86503 United States
Eligibility Criteria
Inclusion Criteria: * Self-identify as American Indian or Alaska Native (AIAN) * Identify as Female * Are 40-74 years of age * Are a registered patient at Chinle Comprehensive HealthCare Facility (CCHFC) * Live within 80 miles of CCHFC * Have not received a mammogram within the prior 12 months * Do not have a personal history of breast cancer * Are not planning to move in the next 6 months * Willing to be randomized Exclusion Criteria: * Do not self-identify as American Indian or Alaska Native (AIAN) * Do not identify as Female * Are not 40-74 years of age * Are not a registered patient at CCHCF * Do not live within 80 miles of CCHCF * Have received a mammogram within the prior 12 months * Have a personal history of breast cancer * Are planning to move in the next 6 months * Unwilling to be randomized
Conditions Metastatic Malignant Neoplasm to Brain, ...
Phase PHASE2
Enrollment 45
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

This research study is studying This research study is studying the efficacy and safety of the following study drugs as a possible treatment for recurrent central nervous system (CNS) metastases: * Palbociclib alone (Cohort 1) * The combination of palbociclib and pembrolizumab (Cohort 2) Pfizer and Merck, pharmaceutical companies, are supporting this research study by providing the study drugs as well as funding for research activities.

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Palbociclib — Administered orally once per day on days 1-21 of 28-day cycles.
  • Drug: Pembrolizumab — Pembrolizumab is administered via intravenous (IV) infusion at a dose of 200 mg over 30 minutes once every 21 days. Pembrolizumab cycles are 3 weeks (21 days) long in this study, and participants in Cohort 2 can receive pembrolizumab as long as they are receiving study drug palbociclib.

Primary Outcomes

  • Intracranial Clinical Benefit Rate (Cohort 1) (8 weeks (Screening through 8 weeks))
  • Intracranial Clinical Benefit Rate (Cohort 2) (8 weeks (Screening through 8 weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2017-02-02
Completion: 2029-09-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 45 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Massachusetts General Hospital
Collaborators: Pfizer, Merck Sharp & Dohme LLC
Principal Investigators:
  • Nancy Wang, MD, MPH (PRINCIPAL_INVESTIGATOR) - Massachusetts General Hospital
Contact Information
Study Contact:
Nancy Wang, MD, MPH
617-724-8770
Nwang6@mgb.org
Nancy Wang, MD, MPH
617-724-8770
Nwang6@mgb.org
Massachusetts General Hospital
Nancy Wang, MD, MPH
Massachusetts General Hospital
Interventions
  • Drug: Palbociclib — Administered orally once per day on days 1-21 of 28-day cycles.
  • Drug: Pembrolizumab — Pembrolizumab is administered via intravenous (IV) infusion at a dose of 200 mg over 30 minutes once every 21 days. Pembrolizumab cycles are 3 weeks (21 days) long in this study, and participants in Cohort 2 can receive pembrolizumab as long as they are receiving study drug palbociclib.
Study Locations (2 sites)
Massachusetts General Hospital, Boston, Massachusetts 02115 United States
Dana Farber Cancer Institute, Boston, Massachusetts 02215 United States
Eligibility Criteria
Inclusion Criteria: * Participants must have histologically or cytologically confirmed disease from any solid tumor (Cohort 1) * Participants must have histologically or cytologically confirmed disease from breast cancer or melanoma (Cohort 2). * Participants must have measurable disease in the CNS, defined as at least one lesion that can be accurately measured in at least one dimension as ≥10 mm. * Participants must have progressive CNS lesions, as defined by one of the following: * Patients may have multiple progressive CNS lesions, some of which have been treated by SRS or surgery. Patients are eligible if they have one or more un-treated (by surgery or SRS) progressive lesions that is measurable. * Patients have measurable residual or progressive lesions after surgery. * Patients who have had prior WBRT and/or SRS are eligible but there needs to be unequivocal evidence of progression of at least one lesion treated by radiation (e.g. tissue diagnosis). Biopsy can be considered for definitive diagnosis. * Patients who have previously been treated with systemic therapy for CNS metastases are eligible. * Age \> 18 years. The toxicity of palbociclib in children is unknown. * ECOG performance status of 0, 1 or 2 (Karnofsky ≥ 60, see Appendix A). * Participants must have normal organ and marrow function as defined below: * leukocytes ≥3,000/mcL * absolute neutrophil count ≥1,500/mcL * platelets ≥100,000/mcL * hemoglobin ≥9g/dL * total bilirubin \< 1.5 x institutional upper limit of normal OR \> 1.5 x institutional upper limit of normal allowed if direct bilirubin is within normal range. * AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal * creatinine within normal institutional limits OR * creatinine clearance ≥60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal (Cohort 1) * creatinine clearance ≥30 mL/min/1.73 m2 for participants with creatinine levels above institutional normal (Cohort 2) * baseline QTc \<480ms * The effects of palbociclib on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of palbociclib administration. * Ability to understand and the willingness to sign a written informed consent document. * Tissue from a prior biopsy or resection of intracranial or extracranial site (primary or metastatic site) for clinical genetic sequencing (at least one FFPE block or 15 unstained slides). Patients previously assessed for genetic sequencing who meet requirements of section 9.2.1 do not need to have additional tissue available for prospective genetic screening. * Presence of alteration in CDK pathway in any biopsy or resection (amplifications in CDK4, CDK6, CCND1, CCND2, CCND3 or CCNE1 or loss of CDKN2A) as described in Section 9.2 using a CLIA-certified assay (Cohort 1 only). * Patients with progressive extracranial disease will not be excluded. * Stable dose of corticosteroids for at least 7 days. * Participants who are HBsAg positive are eligible if they have received HBV anti-viral therapy for at least 4 weeks, and have undetectable HBV viral load prior to enrollment * Note: Participants should remain on anti-viral therapy throughout study intervention and follow local guidelines for HBV anti-viral therapy post completion of study intervention * Hepatits B screening tests are not required unless: * Known history of HBV infection * As mandated by local health authority * Participants with a history of HCV infection are eligible if HCV viral load is undetectable at screening. * Note: Participants must have completed curative anti-viral therapy at least 4 weeks prior to enrollment * Heptatits C screening tests are not required unless: * Known history of HCV infection * As mandated by local health authority Exclusion Criteria * Prior treatment with CDK4/6 inhibitor. * Participants who have had chemotherapy, immunotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have ≥ grade 2 adverse events due to agents administered more than 2 weeks earlier. * Participants who are receiving any other investigational agents. * Participants who are receiving other concurrent chemotherapies or immunotherapies for their cancer (except for patients who will receive letrozole, anastrozole, exemestane, tamoxifen, fulvestrant, trastuzumab, bisphosphonates, or ovarian suppression therapy) * Leptomeningeal involvement of cancer (Cohort 1). Leptomeningeal involvement is allowed for Cohort 2. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib (including abemaciclib). * Participants receiving any medications or substances that are moderate or strong inhibitors or inducers of CYP3A isoenzymes are ineligible. Lists including medications and substances known or with the potential to interact with the CYP3A isoenzymes are provided in Appendix C, and can also be found within section 5.4. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated list such as http://medicine.iupui.edu/clinpharm/ddis/table.aspx; medical reference texts such as the Physicians' Desk Reference may also provide this information. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Pregnant women are excluded from this study because the effect of palbociclib on a developing fetus is unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with palbociclib, breastfeeding should be discontinued if the mother is treated with palbociclib. If a participant inadvertently becomes pregnant while on treatment with pembrolizumab, the participant will be immediately discontinued from study intervention(s). The site will contact the participant at least monthly and document the participant's status until the pregnancy has been completed or terminated. The outcome of the pregnancy will be reported to Merck within 2 working days if the outcome is a serious adverse experience (e.g. death, abortion, congenital anomaly, or other disabling or life-threatening complication to the mother or newborn). The study Investigator will make every effort to obtain permission to follow the outcome of the pregnancy and report the condition of the fetus or newborn to Merck. If a male participant impregnates his female partner, the study personnel at the site must be informed immediately and the pregnancy must be reported to the Overall PI, Merck and Pfizer and followed as necessary. * HIV-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with palbociclib. In addition, these participants are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in participants receiving co
Conditions Breast Cancer Patients
Phase Not Applicable
Enrollment 45
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

This study, delivered by Portsmouth Hospitals University NHS Trust in conjunction with the Research Group in Breast Health at the University of Portsmouth \[1\], aims to assess whether it is possible to test breast biomechanics in women who have had surgery with or without radiotherapy for the treatment of breast cancer.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Primary Outcomes

  • To determine the feasibility of recruitment to a breast biomechanics study in women treated for early breast cancer with surgery +/- adjuvant radiotherapy. (From enrollment to the end of study [through study completion, an average of 1 year])
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-02-06
Completion: 2027-01-28
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 45 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Portsmouth Hospitals NHS Trust
Collaborators: University of Portsmouth
Principal Investigators:
  • Edward St John (PRINCIPAL_INVESTIGATOR) - Portsmouth Hospitals NHS Trust
Contact Information
Study Contact:
Amy Huseyin
02392 286000
Amyrose.Huseyin@porthosp.nhs.uk
Interventions
N/A
Study Locations (1 sites)
Queen Alexandra Hospital, Portsmouth, PO6 3LY United Kingdom
Eligibility Criteria
Inclusion Criteria: * Female * 18 years of age or above * Early or locally advanced breast cancer classified as B5a or B5b (radical treatment intent) * Unilateral breast cancer (contralateral breast used as control) * Receiving or has received breast cancer surgery * +/- Adjuvant radiotherapy * Able to travel to the University of Portsmouth Breast biomechanics laboratory * Participant has capacity to consent. Exclusion Criteria: * Metastatic breast cancer diagnosis * \< 2 weeks post-operative * \< 4 weeks post-radiotherapy * Active post-operative breast infection * Requirement of ongoing breast dressings * Previous breast surgery to contralateral breast * Bilateral breast cancer * Epilepsy (due to strobe on 3D scanner) * Pregnancy or \<6 weeks post-partum * Breastfeeding * Rockwood Frailty score \>5 (or those unable to ambulate un-aided) * Requiring interpreter.
Conditions Breast Cancer
Phase NA
Enrollment 71
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

This study is a single-center, open-label, prospective, clinical cohort study. It enrolled patients in three subgroups: triple negative, HR+HER2-, or HR-HER2+ subtypes, who will receive neoadjuvant treatment according to guidelines. Patients in each subgroup will be divided into two categories: those responsive to neoadjuvant therapy and those resistant to it, based on the efficacy of the treatment. Tumor tissue samples from all enrolled patients before and after neoadjuvant therapy will be collected. We will explore transcriptomic differences in neoadjuvant therapy responders or resisters under the same treatment regimen, as well as transcriptomic changes in tumor tissue before and after treatment, based on single-cell sequencing and spatial transcriptomic technology.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: Single-cell sequencing and spatial transcriptome — Tumor tissue samples of all enrolled patients before and after neoadjuvant therapy were collected. Based on single-cell sequencing and spatial transcriptome technology, the transcriptomic differences in neoadjuvant therapy response or treatment resistance under the same treatment regimen, as well as the transcriptomic changes of tumor tissues before and after treatment were explored.

Primary Outcomes

  • RECIST1.1 Evaluates clinical efficacy (At 24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-04-01
Completion: 2027-04-30
Eligibility
Age: 25 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 71 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Xijing Hospital
Contact Information
Study Contact:
Ju liang J L Zhang
029-84775271
vascularzhang@163.com
Ju liang J L Zhang
029-84775271
vascularzhang@163.com
Xijing hospital
Interventions
  • Diagnostic Test: Single-cell sequencing and spatial transcriptome — Tumor tissue samples of all enrolled patients before and after neoadjuvant therapy were collected. Based on single-cell sequencing and spatial transcriptome technology, the transcriptomic differences in neoadjuvant therapy response or treatment resistance under the same treatment regimen, as well as the transcriptomic changes of tumor tissues before and after treatment were explored.
Study Locations (1 sites)
Xijing hospital, Xi'an, Shaanxi 710032 China
Eligibility Criteria
Inclusion criteria: 1. Voluntary enrollment, able to understand and sign the informed consent form; 2. Female, aged 25 to 70; 3. Meet the indications for neoadjuvant therapy (based on the indicated population clearly defined in the 2023 CSCO Breast Cancer Diagnosis and Treatment Guidelines); 4. No previous systemic treatment for breast cancer; 5. The neoadjuvant treatment regimen met the inclusion requirements: triple-negative breast cancer (T-EC+antiPD-1/T-EC/antiPD-1) HER2+ HR-breast cancer (EC-THP/HP), HER2-HR+ breast cancer (AI/AI+CDK4/6i); 6. Tumor specimens can be obtained (including puncture, minimally invasive, incision biopsy, and surgery); 7. A complete pathological report can be obtained. Exclusion Criteria: 1. The patient did not sign the informed consent form; 2. Tumor specimens cannot be obtained (including puncture, minimally invasive, incision biopsy, and surgery); 3. Patients with severe systemic infections or accompanied by other serious diseases; 4. Have received cytotoxic chemotherapy, endocrine therapy, biological therapy or radiotherapy for any previous reason; 5. Does not meet the indications for neoadjuvant therapy; 6. Neoadjuvant treatment regimens are not included in the neoadjuvant treatment regimens defined in this study; 7. Other circumstances where the researcher deems it unsuitable for inclusion. Criteria for Subjects to withdraw from the study (1) All subjects can voluntarily withdraw at any stage of the study without being discriminated against or retaliated against, and their medical treatment will not be affected. (2) Furthermore, the subjects may withdraw from this study under the following circumstances: 1. Withdrawal decided by the researcher: A: The patient does not meet the indications for the above-mentioned designated neoadjuvant regimen; B: In cases where the subjects are not suitable to continue the trial during the research process, such as when the patients cannot tolerate immunotherapy or chemotherapy, the established neoadjuvant treatment plan needs to be terminated; C: Those who accept the neoadjuvant treatment regimen specified in this study and show disease progression in the cycle evaluation need to terminate the neoadjuvant treatment in advance and undergo surgical resection of the tumor tissue. D: Adverse events occurred. It was judged by the researchers that continuing to participate in the study would have an adverse impact on the safety of the subjects. E: Subjects with poor compliance, which affects the assessment of tolerance; F: The researcher requests the subjects to withdraw from the study for any medical reason; G: The researchers believe that the subjects have other circumstances that make them unsuitable to continue participating in the trial. 2. Voluntary withdrawal of the subjects: A: The subject was unwilling to continue participating in the study and voluntarily withdrew the informed consent form. B: Loss to follow-up (Before loss to follow-up, subjects who have completed three visits should be attempted to be contacted).
Conditions Breast Cancer, Invasive Breast Cancer, C...
Phase Not Applicable
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

Tissue will be procured during a standard of care procedure the patient will already be scheduled to undergo. A one time blood draw will be performed at this time and an optional rectal swab for biome analysis may occur. Follow Up will only consist of chart review to determine date of recurrence, metastases, and/or death

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Procedure: Tissue Sample collection — Tissue sample collected following standard of care procedure patient was already scheduled to have
  • Other: Blood Sample Collection — A one time sample of blood will be collected on day of standard of care procedure
  • Other: Rectal Swab — optional rectal swab may be collected on day of standard of care procedure

Primary Outcomes

  • Tumor biomarker identification (Up to 5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2018-05-10
Completion: 2028-07-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Thomas Jefferson University
Principal Investigators:
  • Nicole Simone, MD (PRINCIPAL_INVESTIGATOR) - Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Contact Information
Study Contact:
Nicole Simone, MD
215-955-6702
Nicole.Simone@jefferson.edu
Nicole Simone
2159556702
Nicole.Simone@jefferson.edu
Sidney Kimmel Cancer Center at Thomas Jefferson University
Interventions
  • Procedure: Tissue Sample collection — Tissue sample collected following standard of care procedure patient was already scheduled to have
  • Other: Blood Sample Collection — A one time sample of blood will be collected on day of standard of care procedure
  • Other: Rectal Swab — optional rectal swab may be collected on day of standard of care procedure
Study Locations (1 sites)
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania 19107 United States
Eligibility Criteria
Inclusion Criteria: * Adults \>18 years old at time of consent * Subject must be capable to giving informed consent or have an acceptable surrogate capable of giving consent on the subject behalf. * Patients with carcinoma in situ or invasive breast cancer * Patient must be undergoing one of the following: * definitive surgical tumor resection for breast cancer OR * placement of a vascular access device as a prelude to neoadjuvant therapy for breast cancer OR * neurosurgical resection of a brain metastasis from primary breast cancer. Exclusion Criteria: * \<18 years old * Not able to give informed consent and does not have acceptable surrogate capable to giving informed consent. * Active drug/alcohol dependence or abuse history
Conditions Advanced/Metastatic Breast Cancer, HER2-...
Phase PHASE2
Enrollment 57
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

Efficacy and Safety of Dalpiciclib Combined with Anti-HER2 Targeted Therapy and Endocrine Therapy as First-line Maintenance Treatment for Patients with Recurrent or Metastatic Hormone-Receptor-Positive, HER2-positive Breast Cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Dalpiciclib — Oral CDK4/6 inhibitor (dose modification permitted for toxicity management)
  • Drug: Trastuzumab (Herceptin) — Subcutaneous, 600mg Q3W; IV: 8mg/kg (loading) → 6mg/kg Q3W
  • Drug: Pertuzumab — IV: 840mg (loading) → 420mg Q3W
  • Drug: Pyrotinib — 240mg qd Week 1 → 320mg qd from Week 2 (max dose); loperamide prophylaxis for diarrhea
  • Drug: Endocrine Therapy 1 — Letrozole 2.5mg, Anastrozole 1mg, Exemestane 25mg, or Fulvestrant 0.5g IM on Days 1, 28 (initial: Days 1, 15, 28)

Primary Outcomes

  • Progression-Free Survival (PFS) (From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years after the last participant completes treatment.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-06-01
Completion: 2029-11-01
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 57 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sun Yat-sen University
Contact Information
Study Contact:
Chen Doctor Chen, PhD / Doctorate
02087341812
chenmt@sysucc.org.cn
Interventions
  • Drug: Dalpiciclib — Oral CDK4/6 inhibitor (dose modification permitted for toxicity management)
  • Drug: Trastuzumab (Herceptin) — Subcutaneous, 600mg Q3W; IV: 8mg/kg (loading) → 6mg/kg Q3W
  • Drug: Pertuzumab — IV: 840mg (loading) → 420mg Q3W
  • Drug: Pyrotinib — 240mg qd Week 1 → 320mg qd from Week 2 (max dose); loperamide prophylaxis for diarrhea
  • Drug: Endocrine Therapy 1 — Letrozole 2.5mg, Anastrozole 1mg, Exemestane 25mg, or Fulvestrant 0.5g IM on Days 1, 28 (initial: Days 1, 15, 28)
Study Locations (1 sites)
Sun yat-Sen University Cancer Center, Guangzhou, Yuexiu District, Guangdong, GUANGZHOU 510060 China
Eligibility Criteria
Inclusion Criteria: 1. Females aged 18 to 75 years with pathologically confirmed metastatic or locally advanced unresectable breast cancer. 2. Hormone receptor (HR)-positive and HER2-positive. 3. Patients with no evidence of disease progression (including CR, PR, or SD)after 4-8 cycles of first-line systemic anti-tumor therapy. 4. ECOG Performance Status: 0-1. Exclusion Criteria: 1. Symptomatic active brain metastases or extensive leptomeningeal metastases. 2. History of Grade 3 or 4 allergic reaction related to the study drugs. 3. Currently receiving other anti-tumor therapies.
Conditions Type 2 Diabetes Mellitus in Obese
Phase NA
Enrollment 60
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to test whether a multi-disciplinary intervention involving exercise and nutrition can slow down the decline in physical function, muscle strength and mass in older adults (aged 65 and above) with Type 2 diabetes (T2D) and obesity treated with Semaglutide. The main questions it aims to answer are: In older people with T2D and obesity, treated with Semaglutide, does a multi-disciplinary intervention of exercise and nutrition compared to standard health recommendations: 1. Reduce the rate of decline in muscle mass? 2. Reduce the rate of decline in muscle strength? 3. Reduce the rate of decline in physical function? Participants will: Administer Semaglutide once weekly for 6 months. Visit the clinic once every 8 weeks for checkups and tests. Keep a diary of their food consumption. Participants in the intervention group will participate in an online exercise program and will receive personal nutritional counseling.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Wegovy (2.4 Mg Dose) + exercise & nutrition — Participants will follow a 26-week, tri-weekly exercise program. One supervised 45-minute session will be conducted weekly via Zoom and recorded, with participants requested to repeat it twice independently on non-consecutive days. The program will include progressive resistance exercises alongside aerobic, balance, and flexibility training. Exercise intensity will be monitored using the Borg RPE scale, progressing gradually to a "somewhat hard" effort level (RPE 13-14). Weekly follow-up calls will track adherence and progress. The nutritional program will include individualized counseling, focusing on protein intake for sarcopenia prevention and personalized dietary adjustments based on health conditions and activity levels. Dietary intake will be monitored through food diaries and an adapted Food Frequency Questionnaire (FFQ). Weight will be tracked through self-reported measurements and on-site visits throughout the study.
  • Other: Wegovy (2.4 Mg Dose) + usual care — Participants allocated to the CG will receive general recommendations for PA according to the medical guidelines for PA for T2D. Guidelines recommend 150 minutes of moderate to vigorous-intensity aerobic activity per week, with no more than 2 consecutive days without activity, or engage in 75 minutes/week of vigorous-intensity or interval training. Incorporate 2-3 sessions/week of resistance exercise, decrease sedentary behavior and add flexibility and balance training 2-3 times/week. PA habits will be collected through a questionnaire during the first and final visit. Nutritional guidance will focus on adequate protein intake and reduced carbohydrate consumption, emphasizing fiber-rich, minimally processed sources. Dietary intake will be evaluated through an FFQ and 3-day food diaries at baseline and study completion.

Primary Outcomes

  • Thigh muscle volume (TMV) (26 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-11
Completion: 2027-11-30
Eligibility
Age: 65 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sheba Medical Center
Collaborators: Hadassah Medical Organization
Principal Investigators:
  • Tali Cukierman - Yaffe, professor (PRINCIPAL_INVESTIGATOR) - Division of Endocrinology, Sheba Medical Center, Israel.
Contact Information
Study Contact:
Tali Cukierman - Yaffe, professor
0523824704
tcukierm@gmail.com
Tal Yahalom-Peri
0544647640
Tal.yahalom@gmail.com
Genya Aharon - Hananel, Dr.
+972 52-557-6455
Genyah@hadassah.org.il
Hadassah Medical Center
Interventions
  • Behavioral: Wegovy (2.4 Mg Dose) + exercise & nutrition — Participants will follow a 26-week, tri-weekly exercise program. One supervised 45-minute session will be conducted weekly via Zoom and recorded, with participants requested to repeat it twice independently on non-consecutive days. The program will include progressive resistance exercises alongside aerobic, balance, and flexibility training. Exercise intensity will be monitored using the Borg RPE scale, progressing gradually to a "somewhat hard" effort level (RPE 13-14). Weekly follow-up calls will track adherence and progress. The nutritional program will include individualized counseling, focusing on protein intake for sarcopenia prevention and personalized dietary adjustments based on health conditions and activity levels. Dietary intake will be monitored through food diaries and an adapted Food Frequency Questionnaire (FFQ). Weight will be tracked through self-reported measurements and on-site visits throughout the study.
  • Other: Wegovy (2.4 Mg Dose) + usual care — Participants allocated to the CG will receive general recommendations for PA according to the medical guidelines for PA for T2D. Guidelines recommend 150 minutes of moderate to vigorous-intensity aerobic activity per week, with no more than 2 consecutive days without activity, or engage in 75 minutes/week of vigorous-intensity or interval training. Incorporate 2-3 sessions/week of resistance exercise, decrease sedentary behavior and add flexibility and balance training 2-3 times/week. PA habits will be collected through a questionnaire during the first and final visit. Nutritional guidance will focus on adequate protein intake and reduced carbohydrate consumption, emphasizing fiber-rich, minimally processed sources. Dietary intake will be evaluated through an FFQ and 3-day food diaries at baseline and study completion.
Study Locations (2 sites)
Hadassah Medical Center, Jerusalem, Israel 5251108 Israel
Sheba medical center, Ramat Gan, Israel 52621 Israel
Eligibility Criteria
Inclusion Criteria: 1. Patients 65 years and above. 2. Patients who were previously diagnosed with type 2 diabetes. 3. Overweight / obesity (body mass index, BMI ≥ 27 kg/m2). Exclusion Criteria: 1. Patients with significant hearing or visual disability. 2. Patients with Estimated Glomerular Filtration Rate (eGFR)\<30 ml/min/1.73 m2. 3. Patients who are in active nutritional therapy. 4. Patients who changed their diet recently (\< 1 month) and/or in a weight-loss program with \>5% weight loss or used anti-obesity drugs in the last 3 months. 5. Patients who reported a weight loss of \>5kg within 90 days of screening 6. Patients who were on Glucagon-like peptide-1 receptor agonists (GLP-1-RA) treatment during the last 3 months. 7. Patients with musculoskeletal disorders, which, by the judgment of the investigators, would limit their ability to perform the exercise training. 8. Patients with neurological diseases, which by the judgment of the investigators, would affect their ability to participate in the trial. 9. Patients with a history of amputation that impairs their ability to participate in the exercise program. 10. Patients with disabilities, which, by the judgment of the investigators, would affect their ability to participate in the trial. 11. Patients who use a walking aid. 12. Patients who are currently using systemic steroids. 13. Patients with active oncological diseases, excluding non-melanoma skin cancer. 14. Patients with diagnosed dementia or cognitive impairment that, in the view of the researchers, may impair their ability to sign a consent form or participate in the trial. 15. Patients who were hospitalized in the past month. 16. Patients who exercise regularly and in the eyes of the examiner will not benefit from the intervention program. 17. Anyone who is not suitable to participate in the study, according to the researcher's discretion. 18. Any contraindication to Magnetic resonance imaging (MRI) (e.g., MRI non-compatible cardiac implantable electronic device, metallic foreign bodies, implantable neurostimulation system, cochlear implants/ear implant, non-removable drug infusion pumps, catheters with metallic components, cerebral artery aneurysm clips which), or inability to perform an MRI scanner (e.g., claustrophobia). 19. Patients who do not fit within the measurement field of view of the Dual-energy X-ray absorptiometry (DXA) scanner in a supine position with the arms next to the body.
Conditions Diabetes Mellitus, Type I, Menstruation
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

Continuous glucose monitors, as a technology that aims to improve glycaemic control in patients with type 1 diabetes, must always adjust to changes in blood glucose levels in these patients, e.g. during sporting activities. In women, in particular, menstruation and its different phases can affect blood glucose levels in different ways. Therefore, this study aims to determine whether there is a different behaviour of blood glucose levels during aerobic or high-intensity exercise in different phases of menstruation. If so, we will try to model this behaviour and create specific guidelines in this regard in terms of physical exercise programming in women. In addition, the information derived from this study will be used to design better artificial pancreas systems that take into account the effects of the menstrual cycle in women.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Other: Aerobic session — This session will consist of an aerobic training session performed on a cycle ergometer.
  • Other: HIIT session — The HIIT exercise will consist of strength exercises with elastic bands.

Primary Outcomes

  • Mean interstitial glucose (24 hours pre-intervention and 24 hours post-intervention)
  • Glycemic variability (24 hours pre-intervention and 24 hours post-intervention)
  • Time spent at each glucose range (24 hours pre-intervention and 24 hours post-intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-10
Completion: 2026-06
Eligibility
Age: 18 Years – 45 Years
Sex: FEMALE
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Valencia
Collaborators: European Regional Development Fund
Contact Information
Study Contact:
Rodrigo Martín-San Agustín, Dr.
0034963983855
rodrigo.martin@uv.es
Rodrigo
963983855
rodrigo.martin@uv.es
University of Valencia
Interventions
  • Other: Aerobic session — This session will consist of an aerobic training session performed on a cycle ergometer.
  • Other: HIIT session — The HIIT exercise will consist of strength exercises with elastic bands.
Study Locations (1 sites)
University of Valencia, Valencia, Select One 46010 Spain
Eligibility Criteria
Inclusion Criteria: Age between 18-45 years T1D with a diabetes duration for more than 2 years Glycated hemoglobin (HbA1c) \< 8.5% (\<69 mmol mol-1) Stable insulin regimen in the past 6 months with less than 20% change in total insulin daily dose Multiple daily injections or insulin pump Weekly physical activity of 90 min or more, but no practicing any sport as amateur or professional. Exclusion Criteria: Clinical conditions or use of medications (other than insulin) known to affect glycemic control (e.g., oral/parenteral steroids or metformin, among others).
Conditions Obesity
Phase PHASE4
Enrollment 3000
Locations 30 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate tirzepatide within a real-world setting to assess body weight loss and incidence of type 2 diabetes in adults without diabetes who have obesity and at least one weight-related comorbid condition. Eligible participants must be registered patients at a participating site. Participation in the study will last about 260 weeks.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Tirzepatide — Administered SC
  • Other: Standard of Care — Standard of care

Primary Outcomes

  • Percent Change from Baseline in Body Weight (Baseline, 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-11-24
Completion: 2032-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 3000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Eli Lilly and Company
Principal Investigators:
  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) (STUDY_DIRECTOR) - Eli Lilly and Company
Contact Information
Study Contact:
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
317-615-4559
LillyTrials@Lilly.com
Physicians interested in becoming principal investigators please contact
clinical_inquiry_hub@lilly.com
Interventions
  • Drug: Tirzepatide — Administered SC
  • Other: Standard of Care — Standard of care
Study Locations (30 sites)
P91604 St John's Medical Centre, Altrincham, WA14 1PF United Kingdom
P89008 Ashton Medical Group, Ashton-under-Lyne, OL6 6EW United Kingdom
Y02319 SSP Bolton General Practice, Bolton, BL1 4TH United Kingdom
P83012 Tower Family Healthcare, Bury, BL9 0NJ United Kingdom
P91014 Washway Road Medical Centre, Cheshire, M33 7SS United Kingdom
P88007 Cheadle Hulme Medical Group (was Cheadle Hulme Health Centre) (Bridge House), Cheshire, SK8 5LL United Kingdom
Y02790 SSP Bolton Medical Centre, Great Lever, BL3 6PY United Kingdom
P89002 The Brooke Surgery, Hyde SK14, SK14 1AT United Kingdom
P84035 Bodey Medical Centre, Manchester, M14 6WP United Kingdom
P84630 The Arch Medical Practice, Manchester, M15 5TJ United Kingdom
Eligibility Criteria
Inclusion Criteria: * Have a body mass index ≥30 and ≤34.9 kilogram per square meter (kg/m2) * Have an increased waist to height ratio (defined by \>0.5) * Have at least one weight related comorbid condition * Have had at least one attempt to lose weight with lifestyle intervention (diet and physical activity) Exclusion Criteria: * Have type 1 diabetes, type 2 diabetes, or any other types of diabetes * Have had a change in body weight of greater than 5 kilograms (11 pounds) within 90 days prior to screening
Conditions Ketosis Prone Diabetes
Phase PHASE4
Enrollment 12
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to quantify day-to-day changes in blood glucose during treatment towards remission in ketosis-prone diabetes (KPDM) and describe them using a mathematical model of KPDM pathogenesis and remission.

Design

Study type: Interventional Phases: Phase4 Allocation: Intervention model: Single Group Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Device: Continuous Glucose Monitoring — After insulin discontinuation participants continue wearing their CGMs, for a total of 3 months.
  • Drug: Insulin — Participants will receive standard-of-care insulin treatment. Insulin dosing will be adjusted based on CGM glucose readings.

Primary Outcomes

  • Quantify Changes in Blood Glucose (Up to 3 months)
  • Development of Mathematical Models (Up to 3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-01-23
Completion: 2027-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 12 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Emory University
Principal Investigators:
  • Priyathama Vellanki, MD, MS (PRINCIPAL_INVESTIGATOR) - Emory University
Contact Information
Study Contact:
Priyathama Vellanki, MD, MS
(404) 778-1687
priyathama.vellanki@emory.edu
Interventions
  • Device: Continuous Glucose Monitoring — After insulin discontinuation participants continue wearing their CGMs, for a total of 3 months.
  • Drug: Insulin — Participants will receive standard-of-care insulin treatment. Insulin dosing will be adjusted based on CGM glucose readings.
Study Locations (2 sites)
Grady Health System, Atlanta, Georgia 30303 United States
Emory University Hospital Midtown, Atlanta, Georgia 30308 United States
Eligibility Criteria
Inclusion Criteria: * Provide informed consent * Have a BMI ≥ 28 kg/m2 * Be of African American ancestry * Meet diagnostic criteria for DKA. Diagnostic criteria for DKA will include a plasma glucose \> 250 mg/dl, a venous pH \< 7.30, a serum bicarbonate \< 18 mmol/l, and serum ketones (beta-hydroxy butyrate) \> 1.5 mmol/L. Exclusion Criteria: * Significant medical or surgical illness including but not limited to myocardial ischemia, congestive heart failure, chronic peripheral venous insufficiency, chronic renal insufficiency, liver insufficiency (serum transaminases 3 times the upper limit of normal) and acute or chronic infectious processes * Have recognized uncontrolled endocrine disorders such as hypercortisolism, acromegaly, or hyperthyroidism * Anemia (hemoglobin \< 12.5 g/dL for men, \<11.5 gm/dL for women), bleeding disorders, or abnormalities in coagulation studies * Pregnant * Diagnosis of diabetes \> 90 days before the presentation of DKA * Unable to give consent